title: Randomized, controlled trial of secondary prevention of coronary sclerosis in normocholesterolemic patients using pravastatin: final 5-year angiographic follow-up of the Prevention of Coronary Sclerosis (PCS) study.
abstract: BACKGROUND
  The potential benefit of cholesterol-lowering therapy for normocholesterolemic patients with coronary artery disease (CAD) has not been clarified. The Prevention of Coronary Sclerosis (PCS) Study was designed to evaluate the effect of pravastatin on secondary prevention of progression of CAD in normocholesterolemic patients for a period of 5 years.
  
  
  METHODS
  A total of 329 patients with CAD were enrolled. Normocholesterolemic patients were defined by a serum total cholesterol (TC) level of 180-219 mg/dl. Patients in this group were randomized into pravastatin and dietary control groups. Patients whose serum TC level fell outside the normal range were divided into a high-cholesterol reference group (TC > or = 220 mg/dl) and a low-cholesterol reference group (TC < 180 mg/dl). Patients in the pravastatin and high-cholesterol groups received pravastatin 10 mg/day. Coronary angiography was performed at baseline, 2 years, and 5 years and analyzed by quantitative coronary arteriography. Angiographic coronary progression was evaluated by minimum obstruction diameter (MOD) and mean segment diameter (MSD).
  
  
  RESULTS
  At 5 years, change in MOD was significantly (change, P=0.033; change/years, P=0.032) less in the pravastatin group (-0.04 +/- 0.17 mm) than in the dietary control group (-0.16 +/- 0.27 mm). Although a similar trend was observed in the MSD results, the differences were not significant.
  
  
  CONCLUSIONS
  Long-term angiographic data show that cholesterol-lowering therapy by pravastatin prevents progression of coronary atherosclerosis in normocholesterolemic patients with CAD.
authors.affiliation: Toyonaka Municipal Hospital, 14-1, Shibaharacho 4-chome, Toyonaka, Osaka, 560-8565, Japan. tomnakag@tcct.zq.ne.jp
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Nakagawa
authors.forename: Tohru
authors.initials: T
authors.lastname: Kobayashi
authors.forename: Nobuhisa
authors.initials: N
authors.lastname: Awata
authors.forename: Shinichi
authors.initials: S
authors.lastname: Sato
authors.forename: Johan H C
authors.initials: JH
authors.lastname: Reiber
authors.forename: Hiromu
authors.initials: H
authors.lastname: Nakajima
authors.forename: Yumiko N
authors.initials: YN
authors.lastname: Toyama
authors.forename: Hisatoyo
authors.initials: H
authors.lastname: Hiraoka
authors.forename: Osamu
authors.initials: O
authors.lastname: Kato
authors.forename: Motohiro
authors.initials: M
authors.lastname: Kirino
authors.forename: Tomoko
authors.initials: T
authors.lastname: Kobayashi
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Takeda
authors.forename: Kenji
authors.initials: K
authors.lastname: Yachiku
authors.forename: Minoru
authors.initials: M
authors.lastname: Iida
authors.forename: Tadao
authors.initials: T
authors.lastname: Itoh
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Shibata
mesh_terms: D000328:Adult; D000368:Aged; D002784:Cholesterol / Q000097:blood; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000097:blood / Q000000981:diagnostic imaging / Q000517:prevention & control*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017035:Pravastatin / Q000627:therapeutic use*; D012016:Reference Values; D013997:Time Factors
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D002784:Cholesterol; D017035:Pravastatin